Skip to main content
SpringerLink
Log in

Reactogenicity and Immunogenicity of a Single Dose of Typhoid Vi Polysaccharide Vaccine in Children Aged between 4 and 14 Years

  • Original Research Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Background: The current study evaluated the reactogenicity and immunogenicity of Typherix™,2 a new typhoid Vi polysaccharide vaccine, in children aged between 4 and 14 years.

Methods: This phase III, open, single-group study was conducted at a single centre in South Africa. Healthy children aged between 4 and 14 years received a single 0.5ml dose containing typhoid Vi polysaccharide vaccine 25µg via intramuscular injection in the left deltoid. Safety and reactogenicity were assessed from solicited and unsolicited signs and symptoms reported during the 5- and 28-day postvaccination follow-up periods. Seropositivity rates against Vi were calculated at 28 days and 6 months after vaccination, and geometric mean titres (GMTs) were also calculated.

Results: A total of 199 children received the vaccine. The according-to-protocol immunogenicity analysis included 185 subjects and showed seropositivity rates of 99.5% [GMT of 2578 enzyme-linked immunosorbent assay (ELISA) units/ml] at day 28 and 94.5% (GMT of 1022 EL.U/ml) at 6 months. Of the 199 subjects included in the reactogenicity analysis, 52.8% reported clinical symptoms, 50.3% reported general symptoms, and 4.0% local symptoms. Solicited symptoms were reported in 46.7% of subjects. Local symptoms and signs were mild and involved mainly swelling. General solicited symptoms were most frequently fever (31.7% of subjects) and headache (14.1%). All general solicited symptoms were mild or moderate except for four reports of fever >39°C. Unsolicited symptoms (mild or moderate) were recorded in 25.1% of subjects, and were most frequently abdominal pain and coughing. No serious adverse events were reported.

Conclusions: TypherixTM typhoid Vi polysaccharide vaccine proved to be well tolerated and immunogenic when administered parenterally to children aged between 4 and 14 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158: 633–8

    Article  CAS  PubMed  Google Scholar 

  2. World Health Organization. International travel and health: vaccination requirements and health advice. Last updated Jan 2000. Available from: URL: http://www.who.int/ith/english/

  3. Centers for Disease Control and Prevention. Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994; 43(No. RR-14): 1–7

    Google Scholar 

  4. Cryz Jr SJ. Patient compliance in the use of Vivotif Berna® vaccine, typhoid vaccine, live oral Ty21a. J Travel Med 1998; 5: 14–7

    Article  PubMed  Google Scholar 

  5. Warren TA, Finder SF, Brier KL, et al. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel. Pharmacoeconomics 1996; 10: 475–83

    Article  CAS  PubMed  Google Scholar 

  6. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 1995; 155: 2293–9

    Article  CAS  PubMed  Google Scholar 

  7. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987; 317: 1101–4

    Article  CAS  PubMed  Google Scholar 

  8. Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14: 435–8

    Article  CAS  PubMed  Google Scholar 

  9. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263–9

    Article  CAS  PubMed  Google Scholar 

  10. Cumberland NS, St Clair Roberts J, Arnold WS, et al. Typhoid Vi: a less reactogenic vaccine. J Int Med Res 1992; 20: 247–53

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PO Box 4833, Welkom, 9460, South Africa

    Helena H. Pelser

Authors
  1. Helena H. Pelser
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

At the time this study was conducted, Dr Pelser was working for the University of the Free State, Bloemfontein, South Africa

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pelser, H.H. Reactogenicity and Immunogenicity of a Single Dose of Typhoid Vi Polysaccharide Vaccine in Children Aged between 4 and 14 Years. BioDrugs 15 (Suppl 1), 13–19 (2001). https://doi.org/10.2165/00063030-200115001-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115001-00003

Keywords

Search

Navigation